Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Magnesium Pantoprazole · 1 trial · 1 indication
A patient is considered at complete remission if he/she achieved symptoms relief and confirmed endoscopic healing at treatment end. A patient achieves symptoms relief if Reflux Questionnaire-GI score ((ReQuest™) stays below 1,73 for at least the three last consecutive treatment days, that can occur at visit V2 or visit V3 for those that did not achieve complete remission at V2 and repeated the treatment for 4 weeks more.
| Arm | Type | Description |
|---|---|---|
| Magnesium Pantoprazole | ACTIVE_COMPARATOR | - |
| Magnesium Esomeprazole | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Magnesium Pantoprazole | DRUG | 1 capsule daily, 40 mg, orally, 30 minutes before breakfast |
| Magnesium Esomeprazole | DRUG | 1 capsule daily, 40 mg, orally, 30 minutes before breakfast |
Inclusion Criteria: * Voluntary participation in the study with signature on Informed Consent Form (ICF) prior to specific protocol procedures * Patients of any race * On outpatient treatment * History of frequent symptom crises related to GERD within the last 3 months (at least a frequency of twic...
Top 1 of 5 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | PHAT | 2 | PHASE3 | Vonoprazan |
Magnesium Pantoprazole is an investigational small molecule developed by Takeda Pharmaceutical Company Limited for gastroesophageal reflux disease, or GERD. It is a magnesium-based formulation of pantoprazole that has been studied in a Phase 3 clinical trial. It is not described as approved and remains in clinical development.
Magnesium Pantoprazole is being developed for the treatment of gastroesophageal reflux disease, commonly known as GERD. Its clinical program has focused on patients with erosive gastroesophageal reflux disease. The drug is investigational and has not been described as approved for any indication.
Magnesium Pantoprazole is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the sponsor of the clinical program evaluating the drug in patients with gastroesophageal reflux disease.
Magnesium Pantoprazole is in Phase 3 development. One Phase 3 trial has been completed, and no trials are currently listed as active. The drug is investigational and is not described as approved by the FDA or any other regulatory agency.
Magnesium Pantoprazole has been evaluated in the Phase 3 trial NCT01132638, titled Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease. The completed trial enrolled 713 patients in Brazil, was randomized, double blind, and active controlled, and included adults 18 years and older.